|
Low nitrite excipients
|
|
9
|
1154
|
April 12, 2024
|
|
🇪🇺 EDQM - Certification of suitability to Monographs of the European Pharmacopoeia
|
|
1
|
297
|
April 12, 2024
|
|
N-nitrososarcosine limit
|
|
2
|
232
|
April 11, 2024
|
|
Whether N-Nitroso Memantine is possible?
|
|
16
|
629
|
April 10, 2024
|
|
SOT posters and talks, (shared posters -update)
|
|
3
|
384
|
April 10, 2024
|
|
Acrostic - facilitating, supporting and documenting read-across!
|
|
4
|
450
|
April 8, 2024
|
|
N-Nitroso Edoxaban Desmethyl Impurity CPCA Score
|
|
6
|
571
|
April 8, 2024
|
|
Claryfying the photo-toxicity of NDEA and colleagues: the link for elucidation of the skin cancers pathogenesis
|
|
0
|
107
|
April 6, 2024
|
|
Nitrosamine Impurity Test Market expected to grow exponentially by 2029
|
|
0
|
419
|
November 19, 2023
|
|
Controversial but Public Report
|
|
4
|
456
|
April 6, 2024
|
|
Theoretical estimation of the conversion of a tertiary amine to nitrosamine
|
|
8
|
755
|
April 6, 2024
|
|
👨💻 Quantitation of MNP & CPNP in Rifampin and Rifapentine by LC-MS/MS
|
|
0
|
241
|
April 5, 2024
|
|
📅 Ascorbic Acid And Alpha-Tocopherol As Nitrite Scavengers - An Elegant And Simple Solution To Mitigate Nitrosamines In Drug Products -Event
|
|
0
|
515
|
April 5, 2024
|
|
Overlapping gene/mutation patterns between changes induced in p53 and RAS oncogenes by some nitrosamines with those induced within photocarcinogenesis: a good start to unravel the puzzle?
|
|
2
|
100
|
April 5, 2024
|
|
Request for risk assessment and confirmatory testing for nortriptyline containing products
|
|
4
|
399
|
April 3, 2024
|
|
AI Limit for Nitroso Nebivolol
|
|
11
|
1943
|
April 3, 2024
|
|
EMA - Update Appendix 3: Enhanced Ames Test conditions for N-nitrosamines
|
|
8
|
843
|
April 2, 2024
|
|
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day
|
|
26
|
3399
|
April 2, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
82
|
7818
|
April 1, 2024
|
|
1st release of Lhasa 'Complex Nitrosamines' data sharing initiative
|
|
6
|
933
|
March 31, 2024
|
|
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub
|
|
1
|
686
|
February 6, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
411
|
March 28, 2024
|
|
Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs) -Pub
|
|
17
|
1987
|
March 28, 2024
|
|
🇨🇦 Health Canada updated the guidance and Appendix 1(March 15, 2024)
|
|
10
|
1472
|
March 27, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
5
|
630
|
March 25, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
563
|
March 22, 2024
|
|
N-Nitrosamine impurity of heterocyclic aromatic ring
|
|
16
|
2582
|
March 22, 2024
|
|
IVACAFTOR (N-Nitroso Ivacaftor)
|
|
0
|
231
|
March 22, 2024
|
|
Nitrosamines in Bacon: a Case Study of Balancing Risks
|
|
1
|
205
|
March 20, 2024
|
|
Nitroso amines quantification in drugs which are having MDD Value more than 10.0g/Day
|
|
2
|
245
|
March 20, 2024
|